Epilepsy

Treatment with STK-001, an antisense oligonucleotide, resulted in significant reductions in seizure activity at the 3- and 6-month timepoints after last dose.

STK-001 (zorevunersen), an investigational therapy, shows promising results in reducing seizures and improving cognition in patients with Dravet syndrome, offering potential beyond current anti-seizure medications.

Radiprodil, a novel NMDA receptor modulator, demonstrated significant potential in reducing seizure frequency, with 71% of patients showing at least a 50% reduction in motor seizures.

Lennox-Gastaut syndrome took an average of 12.3 months to be diagnosed after the first seizure, often leading to delays in treatment.

Representatives from the SCN8A Alliance provided clinical insight on a recently published paper that captured information on the estimated frequency, severity, and prognosis of comorbidities in SCN8A-related disorder phenotypes. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided commentary on the future outlook of gene therapies for patients with epilepsy, and some of the knowledge and technical barriers clinicians currently face. [WATCH TIME: 5 minutes]

Principal investigator Aliza Alter, MD, a pediatric neurologist at the Institute of Neurology in Livingston, New Jersey, provided commentary on a newly initiated phase 2/3 study assessing BHV-7000 as an antiseizure medication.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the parameters of an upcoming educational event that highlights the current and future role of sEEG in epilepsy surgery. [WATCH TIME: 5 minutes]

Study authors concluded that enhanced pre-pregnancy counseling and specialized perinatal care are crucial for safer outcomes in pregnant women with epilepsy.

A recent cohort study reported that use of enzyme-inducing antiseizure medications alongside direct-acting oral anticoagulants was not associated with a difference in risk of thromboembolic events.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy surgery.

In prior research, findings have shown that losartan reduced the risk of epilepsy in patients by blocking astrocyte activation and reducing blood brain barrier damage.

A pair of neurologists from the University of Miami Miller School of Medicine provided insight on the various ways deep brain stimulation has changed and the potential treatment opportunities that lie ahead. [WATCH TIME: 4 minutes]

Results from a survey study suggest the burden of epilepsy is high in sexual and gender minority patient populations, who already experience high risk of stigmatization, discrimination, and poor health outcomes.

Early use of Ceribell’s POC-EEG system significantly improves detection of nonconvulsive seizures, reduces ICU length of stay, and enhances patient outcomes compared to conventional EEG.

The meeting with the American Neurologic Association fosters collaboration, networking, and joint sessions, enhancing knowledge sharing among academic neurologists.

In this episode, the panel discusses the emerging challenges for neurology departments, the shortage of neurologists, and the ways to disseminate between useful and useless information amid a busy career.

John England, MD, and Lisa Merlin, MD, commented on the significant changes to neurology over the years and how education aligns with the latest in treatments advancements and understanding of neurological disorders.

The duo provided insight on a number of key sessions clinicians and neurology educators should attend at the upcoming AUPN Annual Meeting.

Panelists John England, MD, FAAN, and Lisa Merlin, MD, discuss the main objectives of the upcoming AUPN Annual Meeting, set to take place September 14th in Orlando, Florida.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending July 27, 2024. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on congenital muscular dystrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 26, 2024.

The expanded indication, supported by a phase 2 open-label trial, includes children of all ages with CLN2 disease, regardless of whether they are symptomatic or asymptomatic.

Treated patients demonstrated improvements on the Bayley-4 in cognition, communication, and motor function that exceeded those seen in natural history studies of Angelman syndrome.

In the event that a patient inadvertently took a 0.25 mg dose rather than the intended 0.125 mg dose, they are advised to consult a physician.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on progressive multiple sclerosis.